Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

183.50USD
4:02pm GMT
Change (% chg)

$0.52 (+0.28%)
Prev Close
$182.98
Open
$183.19
Day's High
$184.67
Day's Low
$182.84
Volume
247,247
Avg. Vol
1,194,894
52-wk High
$201.23
52-wk Low
$152.16

Latest Key Developments (Source: Significant Developments)

Amgen Reports Aimovig Met All Primary, Secondary Endpoints
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Amgen Inc ::AMGEN REPORTS AIMOVIG™ (ERENUMAB) MET ALL PRIMARY AND SECONDARY ENDPOINTS IN UNIQUE PHASE 3B STUDY IN EPISODIC MIGRAINE PATIENTS WHO HAVE FAILED MULTIPLE PRIOR PREVENTIVE TREATMENTS.AMGEN INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF MAY 17, 2018.AMGEN INC - IF APPROVED, NOVARTIS AND AMGEN WILL CO-COMMERCIALIZE AIMOVIG IN U.S..AMGEN INC - SAFETY DATA ARE CONSISTENT WITH PREVIOUS STUDIES OF AIMOVIG TO DATE.AMGEN INC - LIBERTY ALSO MET ALL SECONDARY ENDPOINTS, INCLUDING REDUCTION OF MONTHLY MIGRAINE DAYS, REDUCTION IN DAYS NEEDING ACUTE MEDICATION.  Full Article

European Commission Approves Amgen, Allergan's Mvasi
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Amgen Inc ::EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER.AMGEN INC - EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR MVASI.  Full Article

Amgen Expects To Launch Migraine Drug This Year
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Amgen Inc ::AMGEN CEO SAYS EXPECTS TO BE ABLE TO LAUNCH AIMOVIG FOR MIGRAINE THIS YEAR.AMGEN SAYS EXPECTS TO LAUNCH HUMIRA BIOSIMILAR OUTSIDE U.S. THIS YEAR.AMGEN CEO SAYS BUSINESS DEVELOPMENT DEALS TO REMAIN PRIORITY IN 2018.AMGEN CEO SAYS COMPANY IN STRONGER STRATEGIC POSITION AFTER TAX REFORM.  Full Article

Biocartis And Amgen Sign New Agreement
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND.AGREEMENT AIMED AT DEVELOPMENT OF IDYLLA(TM) CDX BIOMARKER TESTS .FINANCIAL DETAILS ON NEW CDX AGREEMENT WITH AMGEN ARE NOT DISCLOSED..  Full Article

FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Amgen Inc ::FDA APPROVES XGEVA® (DENOSUMAB) FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA.AMGEN INC - APPROVAL IS BASED ON DATA FROM PIVOTAL PHASE 3 '482 STUDY WHICH ENROLLED 1,718 PATIENTS.  Full Article

Amgen Expects To Incur GAAP Net Tax Expense Of Between $6 Bln And $6.5 Bln
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Amgen Inc ::AMGEN - EXPECTS TO INCUR GAAP NET TAX EXPENSE OF BETWEEN $6 BILLION AND $6.5 BILLION - SEC FILING.AMGEN - EXPECTS TO HAVE ACCESS TO ITS ACCUMULATED GLOBAL CASH AS WELL AS ACCESS TO ITS FUTURE GLOBAL CASH FLOW.AMGEN - UNDER U.S. TAX REFORM LEGISLATION, THE COMPANY’S FUTURE U.S. INCOME GENERALLY WILL BE TAXED AT THE 21 PERCENT U.S. CORPORATE INCOME TAX RATE.AMGEN - UNDER TAX LEGISLATION,EX-U.S. INCOME, INCLUDING PUERTO RICO,GENERALLY WILL BE TAXED IN U.S. AT 10.5% REDUCED BY APPLICABLE FOREIGN TAX CREDITS.AMGEN - NET TAX EXPENSE CHARGE HAS NO IMPACT ON THE COMPANY’S PREVIOUSLY PROVIDED NON-GAAP GUIDANCE.AMGEN - GOING FORWARD, CO DOES NOT EXPECT AN INCREASE IN ITS NON-GAAP TAX RATES AS A RESULT OF THE U.S. TAX REFORM LEGISLATION.  Full Article

Amgen Announces 15 Percent Increase In Q1 2018 Dividend
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES 15 PERCENT INCREASE IN 2018 FIRST QUARTER DIVIDEND.SETS QUARTERLY DIVIDEND OF $1.32PER SHARE.  Full Article

Kyprolis (Carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Amgen Inc ::KYPROLIS® (CARFILZOMIB) EXTENDED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN PHASE 3 ASPIRE TRIAL.AMGEN INC - STUDY MET KEY SECONDARY ENDPOINT OF OS.AMGEN INC - SAFETY DATA FROM ASPIRE WAS CONSISTENT WITH KNOWN SAFETY PROFILE OF KYPROLIS.  Full Article

Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Coherus Biosciences :COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM .COHERUS BIOSCIENCES SAYS ON DEC 7, JUDGE ISSUED UNDER SEAL REPORT AND RECOMMENDATION TO DISTRICT COURT IN RELATION TO PATENT INFRINGEMENT COMPLAINT.COHERUS BIOSCIENCES SAYS CO EXPECTS DISTRICT COURT TO DECIDE IN Q1 2018 WHETHER TO ADOPT MAGISTRATE JUDGE'S RECOMMENDATION - SEC FILING.COHERUS BIOSCIENCES SAYS ‍REPORT AND RECOMMENDATION ISSUED BY JUDGE WITH RESPECT TO LITIGATION BETWEEN AMGEN, AMGEN MANUFACTURING LTD, CO​.  Full Article

Carmot Enters A Multi-Year Drug Discovery Collaboration With Amgen
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Amgen Inc ::CARMOT ENTERS A MULTI-YEAR DRUG DISCOVERY COLLABORATION WITH AMGEN.CARMOT THERAPEUTICS SAYS HAS ENTERED INTO A MULTI-YEAR DRUG DISCOVERY COLLABORATION AND LICENSING AGREEMENT WITH AMGEN.CARMOT THERAPEUTICS SAYS AS PART OF AGREEMENT, CARMOT AND AMGEN WILL WORK TOGETHER TO SELECT THERAPEUTIC TARGETS AND IDENTIFY DRUG CANDIDATES.CARMOT THERAPEUTICS SAYS UNDER AGREEMENT, AMGEN CAN SELECT MULTIPLE TARGETS TO PURSUE AND CARMOT WILL RECEIVE AN UPFRONT PAYMENT AND RESEARCH SUPPORT.CARMOT THERAPEUTICS SAYS IN ADDITION, CARMOT IS ELIGIBLE TO RECEIVE ROYALTIES ON NET SALES OF PRODUCTS RESULTING FROM COLLABORATION.  Full Article

Merck to buy virus-based cancer drug firm Viralytics for $394 million

U.S. drugmaker Merck & Co , already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its pipeline in the sector.